News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Iomab-B Led Allogeneic Hematopoietic Cell Transplantation vs Standard of Care for Older Patients With R/R AML

06/25/2024

According to data from the 2024 EHA Congress, long-term results of the phase 3 SIERRA trial demonstrated that conditioning and induction with 131I-apamistamab (Iomab-B) was well-tolerated and allowed for access to HCT with curative potential...

According to data from the 2024...

06/25/2024

Oncology

News

Olutasidenib Demonstrates Efficacy for Patients With R/R IDH1-Mutated AML Previously Treated With Venetoclax

06/24/2024

Olutasidenib treatment demonstrated efficacy and a consistent safety profile for patients with relapsed/refractory mutant IDH1 acute myeloid leukemia previously treated with venetoclax, according to a subset analysis from a phase 2 study.

Olutasidenib treatment...

06/24/2024

Oncology

News

Reduced-Dose Azacitidine Plus Venetoclax as Maintenance Therapy for Patients With AML Following Intensive or Low-Intensity Induction

06/11/2024

Gina Tomaine

According to a phase 2 trial, low-dose azacitidine plus venetoclax was found to be a feasible maintenance strategy for patients with acute myeloid leukemia following intensive and low-intensity induction.

According to a phase 2 trial,...

06/11/2024

Oncology

Areej El-Jawahri, MD, Massachusetts General Hospital

Conference Coverage

Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS

06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...

Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...

Areej El-Jawahri MD, discusses...

06/01/2024

Oncology

News

Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML

05/31/2024

By Gina Tomaine

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

Decitabine and cedazuridine plus...

05/31/2024

Oncology

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

Venetoclax With Low-Dose Cytarabine Demonstrates Efficacy, Tolerability for Patients With AML at First MRD or Oligoblastic Relapse

04/18/2024

Amber Denham

Venetoclax with low-dose cytarabine is well-tolerated and highly effective among patients with acute myeloid leukemia at first measurable residual disease or oligoblastic relapse, according to a phase 2 study.

Venetoclax with low-dose...

04/18/2024

Oncology

Conference Coverage

Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy

04/09/2024

Featuring Jessica Altman, MD

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...

During the 2024 Great Debates &...

04/09/2024

Oncology

News

Hypomethylating Agents Plus Venetoclax Regimen Post-Allogeneic Hematopoietic Cell Transplant Relapse for Patients With AML

04/02/2024

Jordan Kadish

The combination of hypomethylating agents plus venetoclax post-allogeneic hematopoietic cell transplant relapse demonstrated efficacy among patients with acute myeloid leukemia, with possibly better outcomes among patients with NPM1 and IDH...

The combination of...

04/02/2024

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology